DiaSys Continues International Expansion Through Entrance Into Australian Market; Company Selects Laboratory Diagnostics To Distribute Diagnostics Products in Country.WATERBURY, Conn. -- DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ) a global diagnostics products company, announced today that it has entered into a distribution agreement with Laboratory Diagnostics Pty Ltd., a leading distributor of niche market testing products for both the human and veterinary diagnostic industry in Australia and New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. . Based in Sydney with regional offices in Brisbane and Melbourne, Laboratory Diagnostics represents the leading suppliers of diagnostics from Europe and America. "We continue to rapidly expand into many promising markets," said Greg Witchel, DiaSys Corporation's Chief Executive Officer. "Australia represents a lucrative market, due to the strong sales in the country of animal diagnostic products. The choice of a highly successful distributor such as Laboratory Diagnostics will enable us to rapidly identify and penetrate many of the leaders in the medical industry. In the past two months, we have entered promising markets in Latin America and now Australia. We believe that these initiatives will favorably impact our revenue next year." Laboratory Diagnostics represents leading international human diagnostics companies in the country such as Binax Inc., Alfa Scientific, R Biopharm and Diesse Diagnostica. It also distributes products for such veterinary companies as Institut Pourquier, Synbiotics, VMRD VMRD Veterinary Medical Research and Development, Inc. , BIOX Diagnostics and Biogal. DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. test kits to healthcare and veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. based in Wokingham, England. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion